Ionis Pharmaceuticals Hits New 52-Week High of $66.23
Ionis Pharmaceuticals, Inc. achieved a new 52-week high of USD 66.23 on October 1, 2025, reflecting strong performance in the pharmaceuticals sector. The company reported a 65.37% increase in stock performance over the past year and a significant 243.47% growth in net sales, reaching USD 452.05 million.
Ionis Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 66.23 on October 1, 2025. This achievement underscores the company's robust performance in the pharmaceuticals and biotechnology sector, where it operates as a small-cap entity with a market capitalization of approximately USD 9.72 billion.Over the past year, Ionis Pharmaceuticals has demonstrated impressive growth, with a remarkable 65.37% increase in stock performance, significantly outpacing the S&P 500's 16.09% return. The company reported outstanding results, including a staggering 243.47% growth in net sales, reaching USD 452.05 million. Additionally, the operating cash flow for the year peaked at USD -230.57 million, while raw material costs saw a year-over-year decline of 2.94%.
Ionis Pharmaceuticals also boasts high institutional holdings at 100%, indicating strong confidence from institutional investors who typically have the resources to analyze company fundamentals effectively. With a 52-week low of USD 23.95, the stock's recent performance highlights its upward trajectory in a competitive market.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
